These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33089695)

  • 1. Lipidome Alterations Induced by Cystic Fibrosis, CFTR Mutation, and Lung Function.
    Zardini Buzatto A; Abdel Jabar M; Nizami I; Dasouki M; Li L; Abdel Rahman AM
    J Proteome Res; 2021 Jan; 20(1):549-564. PubMed ID: 33089695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
    Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
    Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis: A Cross-sectional Study.
    Radtke T; Hebestreit H; Gallati S; Schneiderman JE; Braun J; Stevens D; Hulzebos EH; Takken T; Boas SR; Urquhart DS; Lands LC; Tejero S; Sovtic A; Dwyer T; Petrovic M; Harris RA; Karila C; Savi D; Usemann J; Mei-Zahav M; Hatziagorou E; Ratjen F; Kriemler S;
    Ann Am Thorac Soc; 2018 Feb; 15(2):209-216. PubMed ID: 29140739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variant cystic fibrosis phenotypes in the absence of CFTR mutations.
    Groman JD; Meyer ME; Wilmott RW; Zeitlin PL; Cutting GR
    N Engl J Med; 2002 Aug; 347(6):401-7. PubMed ID: 12167682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive metabolic profiles between Cystic Fibrosis mutational subclasses and lung function.
    Masood A; Jacob M; Gu X; Abdel Jabar M; Benabdelkamel H; Nizami I; Li L; Dasouki M; Abdel Rahman AM
    Metabolomics; 2021 Jan; 17(1):4. PubMed ID: 33394183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
    Mickle JE; Cutting GR
    Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
    Yeh JT; Yu YC; Hwang TC
    J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.
    Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M
    PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.
    McCague AF; Raraigh KS; Pellicore MJ; Davis-Marcisak EF; Evans TA; Han ST; Lu Z; Joynt AT; Sharma N; Castellani C; Collaco JM; Corey M; Lewis MH; Penland CM; Rommens JM; Stephenson AL; Sosnay PR; Cutting GR
    Am J Respir Crit Care Med; 2019 May; 199(9):1116-1126. PubMed ID: 30888834
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetics of Cystic Fibrosis: Clinical Implications.
    Egan ME
    Clin Chest Med; 2016 Mar; 37(1):9-16. PubMed ID: 26857764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
    Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
    Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cystic fibrosis transmembrane conductance regulator (CFTR) gene: mutations and clinical phenotypes].
    Schwartz M
    Ugeskr Laeger; 2003 Feb; 165(9):912-6. PubMed ID: 12661515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis.
    Mickle JE; Macek M; Fulmer-Smentek SB; Egan MM; Schwiebert E; Guggino W; Moss R; Cutting GR
    Hum Mol Genet; 1998 Apr; 7(4):729-35. PubMed ID: 9499426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis.
    Cohn JA; Friedman KJ; Noone PG; Knowles MR; Silverman LM; Jowell PS
    N Engl J Med; 1998 Sep; 339(10):653-8. PubMed ID: 9725922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of the cystic fibrosis gene in the lungs].
    Heijerman HG; de Jonge HR
    Ned Tijdschr Geneeskd; 2004 Apr; 148(17):816-9. PubMed ID: 15141646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cystic fibrosis: molecular update and clinical implications].
    Orozco L; Chávez M; Saldaña Y; Velázquez R; Carnevale A; González-del Angel A; Jiménez S
    Rev Invest Clin; 2006; 58(2):139-52. PubMed ID: 16827266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.